Novo Market Capitalization from 2010 to 2024

NVO Stock  USD 106.80  0.67  0.63%   
Novo Nordisk Market Cap yearly trend continues to be very stable with very little volatility. Market Cap is likely to grow to about 781.9 B this year.
Check Novo Nordisk financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novo Nordisk's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.9 B, Interest Expense of 429.4 M or Selling General Administrative of 6.5 B, as well as many indicators such as Price To Sales Ratio of 14.15, Dividend Yield of 0.0154 or PTB Ratio of 30.84. Novo financial statements analysis is a perfect complement when working with Novo Nordisk Valuation or Volatility modules.
  
Check out the analysis of Novo Nordisk Correlation against competitors.

Latest Novo Nordisk's Market Capitalization Growth Pattern

Below is the plot of the Market Cap of Novo Nordisk AS over the last few years. It is Novo Nordisk's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novo Nordisk's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 472.8 B10 Years Trend
Slightly volatile
   Market Cap   
       Timeline  

Novo Market Capitalization Regression Statistics

Arithmetic Mean693,344,593,422
Geometric Mean519,529,004,674
Coefficient Of Variation32.65
Mean Deviation161,658,751,382
Median827,413,567,250
Standard Deviation226,401,731,639
Sample Variance51257744089.1T
Range823.1B
R-Value0.70
Mean Square Error27839493204.2T
R-Squared0.50
Significance0
Slope35,641,819,618
Total Sum of Squares717608417248.1T

Novo Market Capitalization History

2024781.9 B
2023744.7 B
2015827.4 B
2014684.5 B
2013535.5 B
2011515 B
20104.4 B

About Novo Nordisk Financial Statements

Novo Nordisk investors utilize fundamental indicators, such as Market Capitalization, to predict how Novo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk is traded on New York Stock Exchange in the United States.

Pair Trading with Novo Nordisk

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novo Nordisk position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will appreciate offsetting losses from the drop in the long position's value.

Moving together with Novo Stock

  0.78HLN Haleon plcPairCorr
  0.87JNJ Johnson Johnson Sell-off TrendPairCorr
  0.75PFE Pfizer Inc Aggressive PushPairCorr
  0.81ANRO Alto Neuroscience,PairCorr

Moving against Novo Stock

  0.84AXP American Express Fiscal Year End 24th of January 2025 PairCorr
  0.75TRV The Travelers Companies Fiscal Year End 17th of January 2025 PairCorr
  0.72FNMFO Federal National MortgagePairCorr
  0.61KB KB Financial GroupPairCorr
  0.5ITCL Banco Ita ChilePairCorr
The ability to find closely correlated positions to Novo Nordisk could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novo Nordisk when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novo Nordisk - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novo Nordisk AS to buy it.
The correlation of Novo Nordisk is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novo Nordisk moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novo Nordisk AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novo Nordisk can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Check out the analysis of Novo Nordisk Correlation against competitors.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.224
Dividend Share
9.9
Earnings Share
2.99
Revenue Per Share
60.698
Quarterly Revenue Growth
0.214
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.